{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T20:55:06Z","timestamp":1789419306643,"version":"build-2803163510"},"reference-count":112,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:p>There are over 70 known lysosomal storage disorders (LSDs), most caused by mutations in genes encoding lysosomal hydrolases. Central nervous system involvement is a hallmark of the majority of LSDs and, if present, generally determines the prognosis of the disease. Nonetheless, brain disease is currently poorly targeted by available therapies, including systemic enzyme replacement therapy, mostly (but not only) due to the presence of the blood\u2013brain barrier that restricts the access of orally or parenterally administered large molecules into the brain. Thus, one of the greatest and most exciting challenges over coming years will be to succeed in developing effective therapies for the treatment of central nervous system manifestations in LSDs. Over recent years, gene therapy (GT) has emerged as a promising therapeutic strategy for a variety of inherited neurodegenerative diseases. In LSDs, the ability of genetically corrected cells to cross-correct adjacent lysosomal enzyme-deficient cells in the brain after gene transfer might enhance the diffusion of the recombinant enzyme, making this group of diseases a strong candidate for such an approach. Both <jats:italic>in vivo<\/jats:italic> (using the administration of recombinant adeno-associated viral vectors) and <jats:italic>ex vivo<\/jats:italic> (auto-transplantation of lentiviral vector-modified hematopoietic stem cells-HSCs) strategies are feasible. Promising results have been obtained in an ever-increasing number of preclinical studies in rodents and large animal models of LSDs, and these give great hope of GT successfully correcting neurological defects, once translated to clinical practice. We are now at the stage of treating patients, and various clinical trials are underway, to assess the safety and efficacy of <jats:italic>in vivo<\/jats:italic> and <jats:italic>ex vivo<\/jats:italic> GT in several neuropathic LSDs. In this review, we summarize different approaches being developed and review the current clinical trials related to neuropathic LSDs, their results (if any), and their limitations. We will also discuss the pitfalls and the remaining challenges.<\/jats:p>","DOI":"10.3389\/fmolb.2021.624988","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T04:52:15Z","timestamp":1631767935000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":35,"title":["Clinical Trials for Gene Therapy in Lysosomal Diseases With CNS Involvement"],"prefix":"10.3389","volume":"8","author":[{"given":"Caroline","family":"Sevin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumaran","family":"Deiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"103802","DOI":"10.1016\/j.cellimm.2018.04.012","article-title":"Modulation of Immune Responses in Lentiviral Vector-Mediated Gene Transfer","volume":"342","author":"Annoni","year":"2019","journal-title":"Cell Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.1073\/pnas.0306431101","article-title":"Human CD34+ Cells Differentiate into Microglia and Express Recombinant Therapeutic Protein","volume":"101","author":"Asheuer","year":"2004","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41580-019-0185-4","article-title":"Lysosomes as Dynamic Regulators of Cell and Organismal Homeostasis","volume":"21","author":"Ballabio","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.bbamcr.2008.12.001","article-title":"Lysosomal Disorders: from Storage to Cellular Damage","volume":"1793","author":"Ballabio","year":"2009","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Cell Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/dmcn.13600","article-title":"Treatment Strategies for Lysosomal Storage Disorders","volume":"60","author":"Beck","year":"2018","journal-title":"Dev. Med. Child. Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13052-018-0563-0","article-title":"Possible Strategies to Cross the Blood\u2013Brain Barrier","volume":"44","author":"Bellettato","year":"2018","journal-title":"Ital. J. Pediatr."},{"key":"B7","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.omtm.2020.04.001","article-title":"Intra-CSF AAV9 and AAVrh10 Administration in Nonhuman Primates: Promising Routes and Vectors for Which Neurological Diseases?","volume":"17","author":"Bey","year":"2020","journal-title":"Mol. Ther. - Methods Clin. Develop."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1172\/jci28873","article-title":"Gene Therapy of Metachromatic Leukodystrophy Reverses Neurological Damage and Deficits in Mice","volume":"116","author":"Biffi","year":"2006","journal-title":"J. Clin. Invest."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1172\/jci200419205","article-title":"Correction of Metachromatic Leukodystrophy in the Mouse Model by Transplantation of Genetically Modified Hematopoietic Stem Cells","volume":"113","author":"Biffi","year":"2004","journal-title":"J. Clin. Invest."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.ymthe.2017.03.025","article-title":"Hematopoietic Stem Cell Gene Therapy for Storage Disease: Current and New Indications","volume":"25","author":"Biffi","year":"2017","journal-title":"Mol. Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1233158","DOI":"10.1126\/science.1233158","article-title":"Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy","volume":"341","author":"Biffi","year":"2013","journal-title":"Science"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnins.2015.00417","article-title":"Neuroinflammatory Paradigms in Lysosomal Storage Diseases","volume":"9","author":"Bosch","year":"2015","journal-title":"Front. Neurosci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13023-015-0313-y","article-title":"Long-term Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation for Metachromatic Leukodystrophy: the Largest Single-Institution Cohort Report","volume":"10","author":"Boucher","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nrneurol.2013.163","article-title":"Lysosomal Storage Diseases-The Horizon Expands","volume":"9","author":"Boustany","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1146\/annurev.med.57.110104.115650","article-title":"Enzyme Replacement for Lysosomal Diseases","volume":"57","author":"Brady","year":"2006","journal-title":"Annu. Rev. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1128\/cvi.05107-11","article-title":"Adeno-associated Virus Antibody Profiles in Newborns, Children, and Adolescents","volume":"18","author":"Calcedo","year":"2011","journal-title":"Clin. Vaccin. Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1126\/science.1171242","article-title":"Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy","volume":"326","author":"Cartier","year":"2009","journal-title":"Science"},{"key":"B18","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41573-019-0020-9","article-title":"Gene Therapy Targeting Haematopoietic Stem Cells for Inherited Diseases: Progress and Challenges","volume":"18","author":"Cavazzana","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1038\/mt.2008.166","article-title":"Expanded Repertoire of AAV Vector Serotypes Mediate Unique Patterns of Transduction in Mouse Brain","volume":"16","author":"Cearley","year":"2008","journal-title":"Mol. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.ymthe.2005.11.015","article-title":"Transduction Characteristics of Adeno-Associated Virus Vectors Expressing Cap Serotypes 7, 8, 9, and Rh10 in the Mouse Brain","volume":"13","author":"Cearley","year":"2006","journal-title":"Mol. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/nn.4593","article-title":"Engineered AAVs for Efficient Noninvasive Gene Delivery to the central and Peripheral Nervous Systems","volume":"20","author":"Chan","year":"2017","journal-title":"Nat. Neurosci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.ymgme.2011.12.012","article-title":"Mannose-6-phosphate Pathway: A Review on its Role in Lysosomal Function and Dysfunction","volume":"105","author":"Coutinho","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1172-6-55","article-title":"Enzyme Replacement Therapy And\/or Hematopoietic Stem Cell Transplantation at Diagnosis in Patients with Mucopolysaccharidosis Type I: Results of a European Consensus Procedure","volume":"6","author":"De Ru","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/1750-1172-8-189","article-title":"Natural History of Sanfilippo Syndrome in Spain","volume":"8","author":"Delgadillo","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/nrd.2018.110","article-title":"Gene Therapy for Neurological Disorders: Progress and Prospects","volume":"17","author":"Deverman","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"B26","doi-asserted-by":"publisher","first-page":"15053","DOI":"10.1038\/mtm.2015.53","article-title":"Targeted Approaches to Induce Immune Tolerance for Pompe Disease Therapy","volume":"3","author":"Doerfler","year":"2016","journal-title":"Mol. Ther. - Methods Clin. Develop."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1056\/nejmoa1700554","article-title":"Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy","volume":"377","author":"Eichler","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1038\/s41436-019-0522-1","article-title":"Intrathecal Enzyme Replacement for Hurler Syndrome: Biomarker Association with Neurocognitive Outcomes","volume":"21","author":"Eisengart","year":"2019","journal-title":"Genet. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/mt.2010.265","article-title":"Safe, Efficient, and Reproducible Gene Therapy of the Brain in the Dog Models of Sanfilippo and Hurler Syndromes","volume":"19","author":"Ellinwood","year":"2011","journal-title":"Mol. Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmolb.2020.00057","article-title":"Pre-clinical Mouse Models of Neurodegenerative Lysosomal Storage Diseases","volume":"7","author":"Favret","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/trd-160005","article-title":"Lysosomal Storage Diseases","volume":"2","author":"Ferreira","year":"2017","journal-title":"Trd"},{"key":"B32","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1479-7364-5-3-156","article-title":"Lysosomal Storage Disorders: Molecular Basis and Laboratory Testing","volume":"5","author":"Filocamo","year":"2011","journal-title":"Hum. Genomics"},{"key":"B33","doi-asserted-by":"publisher","first-page":"R119","DOI":"10.1093\/hmg\/ddy155","article-title":"The Pathogenesis of Lysosomal Storage Disorders: Beyond the Engorgement of Lysosomes to Abnormal Development and Neuroinflammation","volume":"27","author":"Fiorenza","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"B34","doi-asserted-by":"publisher","first-page":"53","DOI":"10.33176\/AACB-19-00037","article-title":"Laboratory Diagnosis of Lysosomal Diseases: Newborn Screening to Treatment","volume":"41","author":"Fuller","year":"2020","journal-title":"Clin. Biochem. Rev."},{"key":"B35","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/j.ymgme.2019.11.135","article-title":"Lentiviral Hematopoietic Stem and Progenitor Cell Gene Therapy (HSPC-GT) for Metachromatic Leukodystrophy (MLD): Clinical Outcomes from 33 Patients","volume":"129","author":"Fumagalli","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0030-1253412","article-title":"Metachromatic Leukodystrophy - an Update","volume":"41","author":"Gieselmann","year":"2010","journal-title":"Neuropediatrics"},{"key":"B37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1590\/1678-4685-gmb-2016-0268","article-title":"Relative Frequency and Estimated Minimal Frequency of Lysosomal Storage Diseases in Brazil: Report from a Reference Laboratory","volume":"40","author":"Giugliani","year":"2017","journal-title":"Genet. Mol. Biol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/s2352-4642(17)30087-1","article-title":"Neurological Manifestations of Lysosomal Disorders and Emerging Therapies Targeting the CNS","volume":"2","author":"Giugliani","year":"2018","journal-title":"Lancet Child. Adolesc. Health"},{"key":"B39","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.spen.2017.08.005","article-title":"Overview of Inflammation in Neurometabolic Diseases","volume":"24","author":"Grabowski","year":"2017","journal-title":"Semin. Pediatr. Neurol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1001\/jamaneurol.2016.2067","article-title":"Long-Term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Juvenile Metachromatic Leukodystrophy Compared with Nontransplanted Control Patients","volume":"73","author":"Groeschel","year":"2016","journal-title":"JAMA Neurol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"R119","DOI":"10.1093\/hmg\/ddz127","article-title":"Large Animal Models Contribute to the Development of Therapies for central and Peripheral Nervous System Dysfunction in Patients with Lysosomal Storage Diseases","volume":"28","author":"Gurda","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"B42","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/ajmg.a.33779","article-title":"Incidence and Natural History of Mucopolysaccharidosis Type III in France and Comparison with United Kingdom and Greece","volume":"155","author":"H\u00e9ron","year":"2011","journal-title":"Am. J. Med. Genet."},{"key":"B43","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/nejmra1706910","article-title":"Gene Therapy","volume":"381","author":"High","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1089\/hum.2017.026","article-title":"Evaluation of Intrathecal Routes of Administration for Adeno-Associated Viral Vectors in Large Animals","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.omtm.2018.06.003","article-title":"Toxicology Study of Intra-cisterna Magna Adeno-Associated Virus 9 Expressing Human Alpha-L-Iduronidase in Rhesus Macaques","volume":"10","author":"Hordeaux","year":"2018","journal-title":"Mol. Ther. - Methods Clin. Develop."},{"key":"B46","doi-asserted-by":"publisher","first-page":"183336","DOI":"10.1016\/j.bbamem.2020.183336","article-title":"Inherited Disorders of Lysosomal Membrane Transporters","volume":"1862","author":"Huizing","year":"2020","journal-title":"Biochim. Biophys. Acta (BBA) - Biomembranes"},{"key":"B47","first-page":"30152","article-title":"Safety of Intrathecal Delivery of Recombinant Human Arylsulfatase A in Children with Metachromatic Leukodystrophy: Results from a Phase 1\/2 Clinical Trial","author":"\u00ed Dali","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2019.00724","article-title":"Gene Therapy Tools for Brain Diseases","volume":"10","author":"Ingusci","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10545-010-9079-5","article-title":"Clinical Aspects of Neuropathic Lysosomal Storage Disorders","volume":"33","author":"Jardim","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/s0140-6736(03)13311-9","article-title":"Immune Tolerance after Long-Term Enzyme-Replacement Therapy Among Patients Who Have Mucopolysaccharidosis I","volume":"361","author":"Kakavanos","year":"2003","journal-title":"The Lancet"},{"key":"B51","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/b978-0-12-800149-3.00003-2","article-title":"Methods for Gene Transfer to the central Nervous System","volume":"87","author":"Kantor","year":"2014","journal-title":"Advs Genet."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.bbadis.2012.03.012","article-title":"X-linked Adrenoleukodystrophy: Clinical, Metabolic, Genetic and Pathophysiological Aspects","volume":"1822","author":"Kemp","year":"2012","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"103540","DOI":"10.1016\/j.mcn.2020.103540","article-title":"Role of Induced Pluripotent Stem Cells in Lysosomal Storage Diseases","volume":"108","author":"Kido","year":"2020","journal-title":"Mol. Cell Neurosci."},{"key":"B54","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/jimd.12131","article-title":"Treating Lysosomal Storage Disorders: What Have We Learnt?","volume":"43","author":"Lachmann","year":"2020","journal-title":"Jrnl Inher Metab. Disea"},{"key":"B55","doi-asserted-by":"publisher","first-page":"100641","DOI":"10.1016\/j.blre.2019.100641","article-title":"Hematopoietic Stem Cell Gene Therapy: The Optimal Use of Lentivirus and Gene Editing Approaches","volume":"40","author":"Lamsfus-Calle","year":"2020","journal-title":"Blood Rev."},{"key":"B56","doi-asserted-by":"publisher","first-page":"165ra163","DOI":"10.1126\/scitranslmed.3003454","article-title":"Long-term Follow-Up after Gene Therapy for Canavan Disease","volume":"4","author":"Leone","year":"2012","journal-title":"Sci. Translational Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering Adeno-Associated Virus Vectors for Gene Therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat. Rev. Genet."},{"key":"B58","doi-asserted-by":"publisher","first-page":"165772","DOI":"10.1016\/j.bbadis.2020.165772","article-title":"Experimental Gene Therapies for the NCLs","volume":"1866","author":"Liu","year":"2020","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"key":"B59","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.ymthe.2005.06.438","article-title":"Axons Mediate the Distribution of Arylsulfatase A within the Mouse hippocampus upon Gene Delivery","volume":"12","author":"Luca","year":"2005","journal-title":"Mol. Ther."},{"key":"B60","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1177\/0883073819828587","article-title":"Lysosomal Leukodystrophies Lysosomal Storage Diseases Associated with White Matter Abnormalities","volume":"34","author":"Maegawa","year":"2019","journal-title":"J. Child. Neurol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"jcs221739","DOI":"10.1242\/jcs.221739","article-title":"Lysosomal Storage Disorders - Challenges, Concepts and Avenues for Therapy: beyond Rare Diseases","volume":"132","author":"Marques","year":"2019","journal-title":"J. Cell Sci."},{"key":"B62","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.cell.2020.01.017","article-title":"SnapShot: Lysosomal Storage Diseases","volume":"180","author":"Martina","year":"2020","journal-title":"Cell"},{"key":"B63","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.omtm.2019.12.008","article-title":"Immune Response Mechanisms against AAV Vectors in Animal Models","volume":"17","author":"Martino","year":"2020","journal-title":"Mol. Ther. - Methods Clin. Develop."},{"key":"B64","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune Responses to AAV Vectors: Overcoming Barriers to Successful Gene Therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/gim.2015.36","article-title":"A Phase I\/II Study of Intrathecal Idursulfase-IT in Children with Severe Mucopolysaccharidosis II","volume":"18","author":"Muenzer","year":"2016","journal-title":"Genet. Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-017-0635-z","article-title":"Ten Years of the Hunter Outcome Survey (HOS): Insights, Achievements, and Lessons Learned from a Global Patient Registry","volume":"12","author":"Muenzer","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"B67","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1080\/14712598.2019.1607837","article-title":"An Update on Gene Therapy for Lysosomal Storage Disorders","volume":"19","author":"Nagree","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"B68","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/gt.2009.148","article-title":"Progress and Prospects: Immune Responses to Viral Vectors","volume":"17","author":"Nayak","year":"2010","journal-title":"Gene Ther."},{"key":"B69","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3390\/jcm9030616","article-title":"Neuropathophysiology of Lysosomal Storage Diseases: Synaptic Dysfunction as a Starting Point for Disease Progression","volume":"9","author":"Par\u00e1","year":"2020","journal-title":"Jcm"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-017-0662-9","article-title":"Open Issues in Mucopolysaccharidosis Type I-Hurler","volume":"12","author":"Parini","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"B71","doi-asserted-by":"publisher","first-page":"6437","DOI":"10.1523\/jneurosci.22-15-06437.2002","article-title":"Distribution of a Lysosomal Enzyme in the Adult Brain by Axonal Transport and by Cells of the Rostral Migratory Stream","volume":"22","author":"Passini","year":"2002","journal-title":"J. Neurosci."},{"key":"B72","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1134\/s0006297913070043","article-title":"Animal Models for Lysosomal Storage Disorders","volume":"78","author":"Pastores","year":"2013","journal-title":"Biochem. Mosc."},{"key":"B73","doi-asserted-by":"publisher","first-page":"6344","DOI":"10.1128\/jvi.78.12.6344-6359.2004","article-title":"Circulating Anti-wild-type Adeno-Associated Virus Type 2 (AAV2) Antibodies Inhibit Recombinant AAV2 (rAAV2)-Mediated, but Not rAAV5-Mediated, Gene Transfer in the Brain","volume":"78","author":"Peden","year":"2004","journal-title":"J. Virol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s10545-017-0052-4","article-title":"Gene Therapy for Lysosomal Storage Disorders: Recent Advances for Metachromatic Leukodystrophy and Mucopolysaccaridosis I","volume":"40","author":"Penati","year":"2017","journal-title":"J. Inherit. Metab. Dis."},{"key":"B75","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/brainsci10020119","article-title":"Management of Neuroinflammatory Responses to AAV-Mediated Gene Therapies for Neurodegenerative Diseases","volume":"10","author":"Perez","year":"2020","journal-title":"Brain Sci."},{"key":"B76","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1089\/hum.2017.160","article-title":"Clinical Gene Therapy for Neurodegenerative Diseases: Past, Present, and Future","volume":"28","author":"Piguet","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"B77","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1089\/hum.2012.015","article-title":"Correction of Brain Oligodendrocytes by AAVrh.10 Intracerebral Gene Therapy in Metachromatic Leukodystrophy Mice","volume":"23","author":"Piguet","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"B78","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-018-0025-4","article-title":"Lysosomal Storage Diseases","volume":"4","author":"Platt","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B79","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1083\/jcb.201208152","article-title":"Lysosomal Storage Disorders: The Cellular Impact of Lysosomal Dysfunction","volume":"199","author":"Platt","year":"2012","journal-title":"J. Cell Biol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrd.2017.214","article-title":"Emptying the Stores: Lysosomal Diseases and Therapeutic Strategies","volume":"17","author":"Platt","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"B81","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.molmed.2016.12.003","article-title":"Mitochondrial Dysfunction and Neurodegeneration in Lysosomal Storage Disorders","volume":"23","author":"Plotegher","year":"2017","journal-title":"Trends Mol. Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1590\/1678-4685-gmb-2018-0159","article-title":"Lysosomal Diseases: Overview on Current Diagnosis and Treatment","volume":"42","author":"Poswar","year":"2019","journal-title":"Genet. Mol. Biol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.cell.2019.08.053","article-title":"Microglia Biology: One Century of Evolving Concepts","volume":"179","author":"Prinz","year":"2019","journal-title":"Cell"},{"key":"B84","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.bbmt.2018.09.036","article-title":"Survival and Functional Outcomes in Boys with Cerebral Adrenoleukodystrophy with and without Hematopoietic Stem Cell Transplantation","volume":"25","author":"Raymond","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B85","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.imlet.2017.07.004","article-title":"Overview of Immune Abnormalities in Lysosomal Storage Disorders","volume":"188","author":"Rigante","year":"2017","journal-title":"Immunol. Lett."},{"key":"B86","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.ymthe.2006.01.006","article-title":"Gene Therapy for Lysosomal Storage Diseases","volume":"13","author":"Sands","year":"2006","journal-title":"Mol. Ther."},{"key":"B87","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.tins.2011.05.006","article-title":"Clarifying Lysosomal Storage Diseases","volume":"34","author":"Schultz","year":"2011","journal-title":"Trends Neurosciences"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1056\/nejmoa1712649","article-title":"Study of Intraventricular Cerliponase Alfa for CLN2 Disease","volume":"378","author":"Schulz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B89","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/s0140-6736(16)30374-9","article-title":"Lentiviral Haemopoietic Stem-Cell Gene Therapy in Early-Onset Metachromatic Leukodystrophy: an Ad-Hoc Analysis of a Non-randomised, Open-Label, Phase 1\/2 Trial","volume":"388","author":"Sessa","year":"2016","journal-title":"The Lancet"},{"key":"B90","doi-asserted-by":"publisher","first-page":"S129","DOI":"10.1016\/j.ymgme.2017.12.352","article-title":"Intracerebral Gene Therapy in Children with Metachromatic Leukodystrophy: Results of a Phase I\/II Trial","volume":"123","author":"Sevin","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"B91","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1126\/scitranslmed.abb5413","article-title":"Slowing Late Infantile Batten Disease by Direct Brain Parenchymal Administration of a rh.10 Adeno-Associated Virus Expressing CLN2","volume":"12","author":"Sondhi","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"B92","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/sj.mt.6300049","article-title":"Enhanced Survival of the LINCL Mouse Following CLN2 Gene Transfer Using the rh.10 Rhesus Macaque-Derived Adeno-Associated Virus Vector","volume":"15","author":"Sondhi","year":"2007","journal-title":"Mol. Ther."},{"key":"B93","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1089\/hgtb.2012.120","article-title":"Long-term Expression and Safety of Administration of AAVrh.10hCLN2 to the Brain of Rats and Nonhuman Primates for the Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis","volume":"23","author":"Sondhi","year":"2012","journal-title":"Hum. Gene Ther. Methods"},{"key":"B94","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3390\/ijms18010047","article-title":"Subcellular Trafficking of Mammalian Lysosomal Proteins: An Extended View","volume":"18","author":"Staudt","year":"2017","journal-title":"Int. J. Molr Sci."},{"key":"B95","doi-asserted-by":"publisher","first-page":"476","DOI":"10.21037\/atm.2018.11.39","article-title":"Lysosomal Storage Disease Overview","volume":"6","author":"Sun","year":"2018","journal-title":"Ann. Transl. Med."},{"key":"B96","doi-asserted-by":"publisher","first-page":"S130","DOI":"10.1016\/j.ymgme.2016.11.341","article-title":"Intracerebral Administration of rAAV2\/5hNAGLU Vector in Children with MPS IIIB: Results at 30 Months of a Phase I\/II Trial","volume":"120","author":"Tardieu","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"B97","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/s1474-4422(17)30169-2","article-title":"Intracerebral Gene Therapy in Children with Mucopolysaccharidosis Type IIIB Syndrome: an Uncontrolled Phase 1\/2 Clinical Trial","volume":"16","author":"Tardieu","year":"2017","journal-title":"Lancet Neurol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1089\/hum.2013.238","article-title":"Intracerebral Administration of Adeno-Associated Viral Vector Serotype rh.10 Carrying Human SGSH and SUMF1 Cdnas in Children with Mucopolysaccharidosis Type IIIA Disease: Results of a Phase I\/II Trial","volume":"25","author":"Tardieu","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"B99","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ymgme.2018.11.011","article-title":"Enzyme Enhancement Therapeutics for Lysosomal Storage Diseases: Current Status and Perspective","volume":"126","author":"Thomas","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"B100","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.beem.2014.10.001","article-title":"Metachromatic Leukodystrophy: Disease Spectrum and Approaches for Treatment","volume":"29","author":"Van Rappard","year":"2015","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1089\/hum.2017.150","article-title":"Unraveling the Complex Story of Immune Responses to AAV Vectors Trial after Trial","volume":"28","author":"Vandamme","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"B102","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1089\/hum.2016.068","article-title":"Preclinical Testing of the Safety and Tolerability of Lentiviral Vector-Mediated above-Normal Alpha-L-Iduronidase Expression in Murine and Human Hematopoietic Cells Using Toxicology and Biodistribution Good Laboratory Practice Studies","volume":"27","author":"Visigalli","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"B103","doi-asserted-by":"publisher","first-page":"20423","DOI":"10.1074\/jbc.r110.134452","article-title":"Common and Uncommon Pathogenic Cascades in Lysosomal Storage Diseases","volume":"285","author":"Vitner","year":"2010","journal-title":"J. Biol. Chem."},{"key":"B104","doi-asserted-by":"publisher","first-page":"10954","DOI":"10.1073\/pnas.97.20.10954","article-title":"Microglial Activation Precedes Acute Neurodegeneration in Sandhoff Disease and Is Suppressed by Bone Marrow Transplantation","volume":"97","author":"Wada","year":"2000","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B105","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.omtm.2018.09.003","article-title":"Adeno-Associated Virus Neutralizing Antibodies in Large Animals and Their Impact on Brain Intraparenchymal Gene Transfer","volume":"11","author":"Wang","year":"2018","journal-title":"Mol. Ther. - Methods Clin. Develop."},{"key":"B106","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1001\/archneur.60.3.322","article-title":"Insights into the Diagnosis and Treatment of Lysosomal Storage Diseases","volume":"60","author":"Wenger","year":"2003","journal-title":"Arch. Neurol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ymgme.2018.10.006","article-title":"Intrathecal Heparan-N-Sulfatase in Patients with Sanfilippo Syndrome Type A: A Phase IIb Randomized Trial","volume":"126","author":"Wijburg","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"B108","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1089\/hum.2008.022","article-title":"Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis by CNS Administration of a Serotype 2 Adeno-Associated Virus Expressing CLN2 cDNA","volume":"19","author":"Worgall","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1212\/wnl.0000000000004418","article-title":"Developmental Outcomes of Cord Blood Transplantation for Krabbe Disease","volume":"89","author":"Wright","year":"2017","journal-title":"Neurology"},{"key":"B110","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/nyas.13052","article-title":"Disease Models for the Development of Therapies for Lysosomal Storage Diseases","volume":"1371","author":"Xu","year":"2016","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"B111","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1089\/humc.2014.139","article-title":"Intracerebral Gene Therapy Using AAVrh.10-hARSA Recombinant Vector to Treat Patients with Early-Onset Forms of Metachromatic Leukodystrophy: Preclinical Feasibility and Safety Assessments in Nonhuman Primates","volume":"26","author":"Zerah","year":"2015","journal-title":"Hum. Gene Ther. Clin. Develop."},{"key":"B112","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.nbd.2019.01.018","article-title":"Modeling Neuronopathic Storage Diseases with Patient-Derived Culture Systems","volume":"127","author":"Zunke","year":"2019","journal-title":"Neurobiol. Dis."}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2021.624988\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T04:52:19Z","timestamp":1631767939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2021.624988\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":112,"alternative-id":["10.3389\/fmolb.2021.624988"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2021.624988","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,16]]},"article-number":"624988"}}